Kypha is an early-stage company developing new products to improve the way inflammation and immune activity is monitored and treated.
Kypha is currently advancing its lead product, the CompAct™ Test, toward FDA clearance and market launch in 2013. The test uses advanced detection technology and a robust point-of-care format to allow early, accurate detection and real-time monitoring of autoimmune and severe inflammatory disorders. For these patients and their physicians, careful monitoring and early detection are critical to managing disease activity and improving outcomes.
Chad Michael StieningCEOUnconfirmedDr. Stiening is a business development executive with a PhD in life sciences and career focus on technology commercialization. He has studied and worked in the life sciences arena for over 15 years, including academic, large industry and start-up experience. His passion for the "business of science" was realized during his first internship with Monsanto, and evidenced by dual degrees in biology and finance.
Paul Kenneth OlsonPresident and CSOUnconfirmedDr. Olson was co-founder and CSO of Potentia Pharmaceuticals, which developed the world's first complement inhibitor to treat age-related macular degeneration. The drug was acquired in late 2009 by Alcon and is currently in Phase II clinicals. Prior to his start-up experiences, he held research positions at Harvard and Merck. He's worked closely with several world-renowned thought leaders in immunology, gene delivery and ophthalmology.
Andrew Hoyne (Polsinelli Shughart)LawyerUnconfirmed
Marie Carlie, Linda West (Stone Carlie)AccountantUnconfirmed
Invidiual angel investors (US only)Unconfirmed